ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with prednisone in patients with androgen-independent prostate cancer, who have not had previous chemotherapy, is safe and helps to decrease PSA (Prostate-specific antigen) levels.
Prostate Cancer
DRUG: Sagopilone (ZK 219477) + prednisone
PSA Response to treatment with ZK-Epo plus prednisone after 6 cycles, at least 28 days post day 21 of last cycle of treatment
Safety & Tolerability of ZK-Epo plus prednisone, until progression, unknown duration
This study has previously been posted by Berlex, Inc. and Schering AG, Germany.Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc., Schering AG Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer HealthCare Pharmaceuticals, Inc.and Bayer Schering Pharma AG, Germany are the sponsors of the trial.